Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

28.2K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
28.2K
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

1.0K
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
1.0K
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

162
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
162
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

59
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
59
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heterozygous RNF13 Truncating Variants Are Associated With Developmental and Epileptic Encephalopathy.

American journal of medical genetics. Part A·2026
Same author

Comprehensive classification of HCN1 variants linked to neurodevelopmental disorders with and without epilepsy.

bioRxiv : the preprint server for biology·2026
Same author

High-Density EEG Source Localisation of averaged interictal epileptic Discharges validated by surgical Outcome.

Scientific data·2025
Same author

Novel Mutation at Cys225 in <i>GNAO1</i>-Associated Developmental and Epileptic Encephalopathies: Clinical, Molecular, and Pharmacological Profiling of Case Studies.

MedComm·2025
Same author

Pearls & Oy-sters: Increased Visibility of Focal Cortical Dysplasia in Cerebral MRI During the First Year of Life.

Neurology·2024
Same author

Paroxysmal events in glucose transporter type 1 deficiency syndrome: Early identification of their true nature is important.

Developmental medicine and child neurology·2024

Related Experiment Video

Updated: Mar 24, 2026

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
07:45

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

Published on: October 21, 2014

8.5K

Clinical Variability of GLUT1DS.

Anastasia Martinez-Esteve Melnikova1, Christian M Korff1

  • 1Pediatric Neurology, Child and Adolescent Department, University Hospitals, Geneva, Switzerland.

Pediatric Neurology Briefs
|March 3, 2016
PubMed
Summary

Researchers compared familial and sporadic glucose transporter type 1 deficiency syndrome (GLUT1DS) caused by SLC2A1 gene mutations. The study aimed to identify clinical and genetic distinctions between these two patient groups.

Keywords:
EpilepsyGLUT1 deficiency syndromeKetogenic dietParoxysmal exercise-induced dyskinesiaSLC2A1 gene

More Related Videos

Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice
08:27

Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice

Published on: March 11, 2020

6.7K
Measuring Glucose Uptake in Drosophila Models of TDP-43 Proteinopathy
07:07

Measuring Glucose Uptake in Drosophila Models of TDP-43 Proteinopathy

Published on: August 3, 2021

3.2K

Related Experiment Videos

Last Updated: Mar 24, 2026

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
07:45

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

Published on: October 21, 2014

8.5K
Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice
08:27

Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice

Published on: March 11, 2020

6.7K
Measuring Glucose Uptake in Drosophila Models of TDP-43 Proteinopathy
07:07

Measuring Glucose Uptake in Drosophila Models of TDP-43 Proteinopathy

Published on: August 3, 2021

3.2K

Area of Science:

  • Neurogenetics
  • Metabolic disorders
  • Pediatric neurology

Background:

  • Glucose transporter type 1 deficiency syndrome (GLUT1DS) is a rare neurological disorder.
  • It is primarily caused by mutations in the SLC2A1 gene, affecting glucose transport to the brain.
  • GLUT1DS can present with familial (inherited) or sporadic (de novo) genetic origins.

Purpose of the Study:

  • To investigate potential clinical and genetic variations between patients with familial SLC2A1 mutations and those with sporadic SLC2A1 mutations.
  • To enhance the understanding of genotype-phenotype correlations in GLUT1DS.

Main Methods:

  • Retrospective analysis of 22 patients diagnosed with GLUT1DS.
  • Categorization of patients into familial (n=11) and sporadic (n=11) mutation groups based on SLC2A1 gene analysis.
  • Comparison of clinical manifestations and genetic findings between the two groups.

Main Results:

  • The study compared 11 patients with familial SLC2A1 mutations to 11 patients with sporadic mutations.
  • Analysis focused on documenting clinical and genetic differences between these two GLUT1DS patient cohorts.

Conclusions:

  • The findings aim to clarify whether familial and sporadic GLUT1DS present distinct clinical or genetic profiles.
  • Understanding these differences can inform diagnosis, prognosis, and management strategies for GLUT1DS.